CF PharmTech, Inc engages in the research, development, production and sale of respiratory diseases pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 574 full-time employees. The company went IPO on 2025-10-08. The Company’s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The firm's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The firm mainly conducts its business in the domestic market.
02652.HK stock price ended at $0 on 수요일, after dropping NaN%
On the latest trading day Jan 21, 2026, the stock price of 02652.HK fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for 02652.HK decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.
02652.HK 기술적 시그널
기술적 시그널 요약
구매 신호 0
중립 신호 7
매도 신호 0
Strong Sell
Sell
Neutral
Buy
Strong Buy
02652.HK은 현재 0개의 매수 신호와 0개의 매도 신호를 보이고 있습니다. 이 주식은 -- 이후로 하락 추세 상태에 있으며, 이 기간 동안 총 가격 변동률은 --입니다. 전반적으로 기술적 지표들은 중기적으로 Neutral 전망을 나타내고 있습니다.
02652.HK에 대한 강세/약세 신호
이동평균, RSI, MACD, 거래량 등 핵심 지표를 분석하여 02652.HK 의 강세/약세 시그널을 생성합니다. 이 인사이트를 활용해 더 현명한 투자 결정을 내리세요.